Retrospective Study
Copyright ©The Author(s) 2021.
World J Clin Cases. Jul 16, 2021; 9(20): 5453-5461
Published online Jul 16, 2021. doi: 10.12998/wjcc.v9.i20.5453
Table 1 Clinical and demographical characteristics of patients categorized by Gensini score
Gensini score = 0
Low-Gensini score
High-Gensini score
P value1
P value
P value
P value
0
7 (4, 11)
34 (24, 52)
(Group 1-2)
(Group 1-3)
(Group 2-3)
Number of patients160126282584
Age (yr)62 (55, 69)64 (57, 69)67 (61, 73)< 0.001< 0.001< 0.001< 0.001
Male, n (%)826 (51.6)1474 (56.1)1790 (69.3)< 0.001< 0.001< 0.001< 0.001
Waist circumference82 (80, 87)82 (80, 87)82 (80, 87)< 0.0010.6930.0020.002
BMI, kg/m224.4 (22.1, 26.8)24.3 (22.2, 26.6)24.2 (22.2, 26.3)0.0280.2820.0470.284
Hypertension, n (%)756 (47.2)1441 (54.8)1724 (66.7)< 0.001< 0.001< 0.001< 0.001
DM, n (%)194 (12.1)406 (15.4)658 (25.5)< 0.001< 0.001< 0.001< 0.001
Smoking, n (%)228 (14.2)427 (16.2)514 (19.9)< 0.0010.08< 0.0010.001
Family history of ASCVD4 (0.2)35 (1.3)110 (4.3)< 0.001< 0.001< 0.001< 0.001
EF, %55.65 (38, 65.09)68 (62.9, 72.7)66.8 (61.3, 72)< 0.001< 0.001< 0.001< 0.001
Glucose, mmol/L5.45 (4.92, 6.39)5.53 (4.95, 6.60)5.76 (5.07, 7.15)< 0.001< 0.001< 0.001< 0.001
eGFR93.3 (80.9, 102.1)91.5 (80, 100)88 (74, 97.9)< 0.001< 0.001< 0.001< 0.001
NT-ProBNP95 (45, 320)79 (40, 209.75)131 (59, 377.75)< 0.001< 0.001< 0.001< 0.001
Triglyceride4.34 (3.64, 5.059)4.19 (3.45, 5.03)4.099 (3.45, 4.97)0.0260.8850.0290.019
TC1.39 (0.99, 1.99)1.38 (1, 1.9775)1.45 (1.03, 2.04)0.0120.001< 0.0010.189
LDL-C2.33 (1.74, 2.88)2.19 (1.62, 2.87)2.16 (1.64, 2.83)0.03< 0.001< 0.0010.687
HDL-C0.94 (0, 1.11)0.9325 (0, 1.1)0.88 (0, 1.03)< 0.0010.092< 0.001< 0.001
China-PAR5.3 (3.1, 7.9)6 (3.8, 8.9)8.5 (5.8, 12.2)< 0.001< 0.001< 0.001< 0.001
< 5%, n (%)744 (46.5)1009 (38.4)454 (17.6)< 0.001< 0.001< 0.001< 0.001
5%-10%, n (%)616 (38.5)1115 (42.4)1150 (44.5)< 0.001< 0.001< 0.001< 0.001
> 10%, n (%)241 (15.1)504 (19.2)980 (37.9)< 0.001< 0.001< 0.001< 0.001
Values are expressed as the mean ± SD or n (%), median (minimum–maximum).
1ANOVA, Kruskal–Wallis, or Pearson chi-square test was used to compare variables among three groups. CAD: Coronary artery disease; BMI: Body mass index; DM: Diabetes mellitus; ASCVD: Atherosclerotic cardiovascular disease; EF: Ejection fraction; eGFR: Epidermal growth factor receptor; LDL-C: Low-density lipoprotein cholesterol; HDL-C: High-density lipoprotein cholesterol; China-PAR: Prediction for atherosclerotic cardiovascular disease risk in China.
Table 2 Baseline characteristics of patients with or without coronary artery disease
Non-CAD
CAD
P value1
Number of patients33653448
Age (yr)62 (56, 69)67 (60, 73)< 0.001
Male, n (%)1778 (52.8)2312 (67.1)< 0.001
Waist circumference82 (80, 87)82 (80, 87)0.026
BMI, kg/m2 24.4 (22.3, 26.7)24.2 (22.2, 26.3)< 0.001
Hypertension, n (%)1660 (49.3)2261 (65.6)< 0.001
DM, n (%)417 (12.4)841 (24.4)< 0.001
Smoking, n (%)501 (14.9)668 (19.4)< 0.001
Family history of ASCVD21 (0.6)128 (3.7)< 0.001
EF, n (%)67.3 (62, 72.2)67 (61.8, 72.09)0.071
Glucose, mmol/L5.46 (4.92, 6.44)5.72 (5.059, 7.05)< 0.001
eGFR93 (81.3, 101.3)88.34 (74.7, 97.98)< 0.001
NT-ProBNP83 (41, 249)116 (54, 328)< 0.001
Triglyceride1.38 (0.99, 1.98)1.44 (1.03, 2.03)0.009
TC4.28 (3.55, 5.06)4.12 (3.44, 4.98)< 0.001
LDL-C2.27 (1.69, 2.88)2.15 (1.63, 2.83)0.323
HDL-C1.11 (0.94, 1.31)1.05 (0.89, 1.24)< 0.001
China-PAR5.4 (3.4, 8.0)8.2 (5.4, 12.0)< 0.001
< 5%, n (%)1497 (44.5)710 (20.6)< 0.001
5%-10%, n (%)1380 (41.0)1501 (43.5)< 0.001
> 10%, n (%)488 (14.5)1237 (35.9)< 0.001
Gensini score 2 (0, 5)26 (16, 45)< 0.001
Values are expressed as the mean ± SD or n (%), median (minimum–maximum).
1P values from ANOVA or Kruskal–Wallis test as appropriate for continuous variables and with Chi-square test for categorical variables. CAD: Coronary artery disease; BMI: Body mass index; DM: Diabetes mellitus; ASCVD: Atherosclerotic cardiovascular disease; EF: Ejection fraction; eGFR: Epidermal growth factor receptor; LDL-C: Low-density lipoprotein cholesterol; HDL-C: High-density lipoprotein cholesterol; China-PAR: Prediction for atherosclerotic cardiovascular disease risk in China.